Lawrence Howard Schwartz

Lawrence Howard Schwartz's AcademicInfluence.com Rankings

Philosophy

#5338

World Rank

#8106

Historical Rank

Logic

#2632

World Rank

#3648

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Lawrence Howard Schwartz's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Lawrence Howard Schwartz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence Howard Schwartz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009) (17488)
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) (2015) (3526)
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. (2011) (1735)
Artificial intelligence in radiology (2018) (1426)
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) (1335)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. (2017) (1304)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) (1153)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. (2005) (1127)
RECIST 1.1-Update and clarification: From the RECIST committee. (2016) (944)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. (2005) (898)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. (2004) (741)
Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection (2008) (690)
Artificial intelligence in cancer imaging: Clinical challenges and applications (2019) (689)
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003) (662)
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (632)
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. (2009) (510)
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection (2003) (462)
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. (2006) (411)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. (2006) (405)
Reproducibility of radiomics for deciphering tumor phenotype with imaging (2016) (387)
Improving communication of diagnostic radiology findings through structured reporting. (2011) (385)
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. (2010) (378)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. (2016) (353)
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. (2009) (304)
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. (2016) (303)
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus (2007) (297)
NCCN clinical practice guidelines in oncology: kidney cancer. (2009) (286)
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer (2007) (274)
Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. (2006) (264)
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. (2016) (260)
Prevalence and importance of small hepatic lesions found at CT in patients with cancer. (1999) (254)
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. (2000) (250)
Evaluation of lymph nodes with RECIST 1.1. (2009) (235)
Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. (2005) (228)
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. (2010) (227)
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. (1998) (215)
Sorafenib for Advanced and Refractory Desmoid Tumors (2018) (214)
Renal masses: characterization with diffusion-weighted MR imaging--a preliminary experience. (2008) (212)
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. (2005) (208)
MR imaging of the breast in patients with occult primary breast carcinoma. (1997) (208)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
Test–Retest Reproducibility Analysis of Lung CT Image Features (2014) (205)
Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. (2003) (204)
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. (2009) (200)
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. (2002) (198)
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. (1997) (194)
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. (2005) (191)
Automatic detection of small lung nodules on CT utilizing a local density maximum algorithm (2003) (189)
Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials (2018) (183)
Phase II trial of bortezomib for patients with advanced renal cell carcinoma. (2004) (180)
Individual patient data analysis to assess modifications to the RECIST criteria. (2009) (180)
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. (2001) (176)
Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases (2008) (175)
NCCN clinical practice guidelines in oncology: testicular cancer. (2009) (173)
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. (2016) (172)
CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. (2011) (171)
Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society (2004) (169)
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC (2016) (169)
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (2017) (169)
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. (1994) (166)
Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. (2007) (160)
Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. (2013) (157)
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. (1995) (155)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 (2008) (150)
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. (2004) (148)
Liver segmentation for CT images using GVF snake. (2005) (147)
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma (2006) (147)
Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. (1999) (141)
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. (2009) (140)
Quantitative imaging biomarkers: A review of statistical methods for computer algorithm comparisons (2014) (139)
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards (2005) (136)
Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer (2012) (132)
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. (2012) (130)
Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy (2005) (123)
Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. (2003) (122)
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. (2006) (119)
Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer (2005) (118)
Lung cancer: computerized quantification of tumor response--initial results. (2006) (118)
Validation of novel imaging methodologies for use as cancer clinical trial end-points. (2009) (117)
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. (2012) (117)
Endometrial stromal sarcoma: objective response to letrozole. (2001) (117)
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). (2016) (113)
Recommendations for the assessment of progression in randomised cancer treatment trials. (2009) (111)
Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings (2016) (111)
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. (2001) (110)
A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development (2010) (109)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. (1999) (106)
Exploring Variability in CT Characterization of Tumors: A Preliminary Phantom Study. (2014) (102)
Lessons learned from independent central review. (2009) (101)
Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. (2013) (101)
Evaluation of tumor measurements in oncology: use of film-based and electronic techniques. (2000) (100)
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. (2006) (98)
Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. (2006) (97)
Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. (2000) (97)
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. (1999) (96)
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. (2012) (95)
Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. (2010) (91)
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. (2018) (91)
Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules (2019) (90)
Quantitative Imaging in Cancer Clinical Trials (2016) (90)
Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography. (1998) (89)
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. (2009) (89)
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers* (2009) (88)
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. (2011) (88)
A statistical simulation study finds discordance between WHO criteria and RECIST guideline. (2004) (88)
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. (2012) (87)
18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor (2018) (86)
Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results (2011) (86)
Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. (2021) (86)
Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. (1999) (85)
Preoperative radiographic assessment of hepatic steatosis with histologic correlation. (2008) (85)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors (2009) (84)
Gemcitabine‐related radiation recall preferentially involves internal tissue and organs (2004) (84)
Promise and pitfalls of quantitative imaging in oncology clinical trials. (2012) (83)
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. (2009) (83)
Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy (2008) (83)
Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease (2011) (81)
Gallbladder Carcinoma: Findings at MR Imaging With MR Cholangiopancreatography (2002) (81)
Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. (2003) (80)
Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab (2017) (80)
Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. (1996) (79)
BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL (2017) (78)
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans (2010) (77)
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics (2019) (76)
Phase II Trial of Arsenic Trioxide in Patients with Metastatic Renal Cell Carcinoma (2002) (76)
Marker-controlled watershed for lymphoma segmentation in sequential CT images. (2006) (76)
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. (2020) (75)
Automated Quantification of Body Fat Distribution on Volumetric Computed Tomography (2006) (73)
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas (2006) (73)
Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. (2013) (72)
Radiation therapy in the treatment of difficult giant cell tumors. (1989) (72)
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response (2011) (72)
Update on colorectal cancer imaging. (2012) (71)
Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors (2007) (70)
Prospective comparison of T2-weighted fast spin-echo, with and without fat suppression, and conventional spin-echo pulse sequences in the upper abdomen. (1993) (67)
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. (2019) (67)
Lymph node segmentation from CT images using fast marching method. (2004) (67)
Feasibility of using limited‐population‐based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast‐enhanced MRI data (2008) (66)
Adrenal masses in patients with malignancy: prospective comparison of echo-planar, fast spin-echo, and chemical shift MR imaging. (1995) (66)
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. (2003) (66)
Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics (2020) (65)
Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. (2008) (64)
Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies (2012) (63)
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. (2011) (61)
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. (2009) (60)
Hybrid detection of lung nodules on CT scan images. (2015) (59)
Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results (2011) (58)
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors (2015) (57)
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. (2011) (56)
Imaging response assessment in oncology (2006) (55)
Comparison of magnetic resonance and endoscopic retrograde cholangiopancreatography in malignant pancreaticobiliary obstruction. (1999) (55)
Pulmonary metastases: effect of CT section thickness on measurement--initial experience. (2005) (54)
Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. (2000) (53)
A simulation study to evaluate the impact of the number of lesions measured on response assessment. (2009) (53)
CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study (2018) (53)
Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. (2005) (53)
Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001) (2009) (52)
The use of volumetric CT as an imaging biomarker in lung cancer. (2010) (51)
Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. (2009) (50)
Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen? (1997) (50)
Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population (2010) (49)
Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. (2009) (48)
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer (2008) (48)
Misrepresentation of publications by applicants for radiology fellowships: is it a problem? (1997) (48)
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. (2010) (47)
Retained seminal vesicles after radical prostatectomy: frequency, MRI characteristics, and clinical relevance. (2006) (47)
Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study (2020) (47)
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. (2010) (47)
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. (2012) (46)
Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease (1998) (46)
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation (2011) (45)
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies (2004) (45)
Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? (2012) (44)
Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography (2019) (44)
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 (2020) (44)
Hepatic intraductal oncocytic papillary carcinoma (2002) (43)
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival (2010) (43)
Recognition of Intrabiliary Hepatic Metastases From Colorectal Adenocarcinoma (2000) (42)
How to assess anti-tumour efficacy by imaging techniques. (2008) (42)
The use of imaging in the diagnosis and staging of hepatobiliary malignancies. (2007) (42)
Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography. (2019) (42)
Fully Automatic Brain Tumor Segmentation from Multiple MR Sequences using Hidden Markov Fields and Variational (2013) (42)
Shape-Constraint Region Growing for Delineation of Hepatic Metastases on Contrast-Enhanced Computed Tomograph Scans (2006) (41)
Hepatic arterial infusion of floxuridine and dexamethasone plus high‐dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma (2005) (41)
Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment. (1998) (41)
Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy (2008) (41)
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
Automatic Liver Segmentation by Integrating Fully Convolutional Networks into Active Contour Models. (2019) (39)
Bone marrow segmentation in leukemia using diffusion and T 2 weighted echo planar magnetic resonance imaging (2000) (39)
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. (2019) (39)
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy (2016) (38)
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging (2017) (38)
Complex postcholecystectomy biliary disorders: preliminary experience with evaluation by means of breath-hold MR cholangiography. (1998) (38)
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials (2003) (37)
Imaging of hepatocellular carcinoma: a practical approach. (2001) (37)
High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma (2004) (37)
Recurrent gallbladder carcinoma along laparoscopic cholecystectomy port tracks: CT demonstration. (1999) (36)
Eye Tracking for Deep Learning Segmentation Using Convolutional Neural Networks (2019) (36)
An Automatic Method for Ground Glass Opacity Nodule Detection and Segmentation from CT Studies (2006) (35)
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma (2003) (35)
MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. (1998) (35)
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. (2013) (35)
Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. (2007) (35)
Multiphasic contrast‐enhanced MRI: Single‐slice versus volumetric quantification of tumor enhancement for the assessment of renal clear‐cell carcinoma fuhrman grade (2013) (35)
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. (2006) (34)
Semiautomatic segmentation of liver metastases on volumetric CT images. (2015) (33)
iRECIST: how to do it (2020) (33)
Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials (2014) (33)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors (2012) (32)
Kinetics of liver volume changes in the first year after portal vein embolization. (2010) (32)
Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status (2017) (31)
Non-neoplastic causes of high signal intensity at T2-weighted MR imaging after treatment for musculoskeletal neoplasm (1995) (30)
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. (2016) (30)
Quantitative Volumetric CT-Histogram Analysis in N-Staging of 18F-FDG–Equivocal Patients with Lung Cancer (2014) (30)
Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. (1998) (30)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. (2004) (29)
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. (2021) (29)
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer (2021) (29)
Automatic Detection and Segmentation of Ground Glass Opacity Nodules (2006) (28)
Application of Radiomics in Predicting the Malignancy of Pulmonary Nodules in Different Sizes. (2019) (28)
Voice recognition in radiology reporting. (1997) (28)
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). (2019) (28)
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab (2019) (28)
Case report. Adrenocortical oncocytoma: CT and MRI findings. (1996) (27)
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. (2018) (27)
Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under “No Change” Conditions12 (2015) (27)
The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. (2018) (27)
Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients (2017) (27)
Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. (2015) (26)
Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma (2008) (26)
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. (2020) (25)
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). (2020) (25)
Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma (2004) (25)
Gemcitabine-induced pulmonary toxicity. (2012) (25)
Non-Hodgkin lymphoma in skeletal muscle manifesting as homogeneous masses with CT attenuation similar to muscle (1997) (25)
Paclitaxel in germ cell cancer. (1995) (25)
Toward Generalizability in the Deployment of Artificial Intelligence in Radiology: Role of Computation Stress Testing to Overcome Underspecification (2021) (24)
Breath‐Hold Magnetic Resonance Cholangiopancreatography in the Evaluation of Malignant Pancreaticobiliary Obstruction (2003) (24)
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST (2020) (24)
Future vision for the quality assurance of oncology clinical trials (2013) (24)
Breast cancer: assessing the use of routine pelvic CT in patient evaluation. (2001) (24)
Medical Imaging in Clinical Trials (2014) (24)
CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 Lung Adenocarcinoma. (2019) (22)
Reliability of Radiomic Features Across Multiple Abdominal CT Image Acquisition Settings: A Pilot Study Using ACR CT Phantom (2019) (22)
Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours (2012) (22)
Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor (2016) (22)
A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2005) (22)
MR imaging of carcinoma within urinary bladder diverticulum. (1997) (22)
Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. (1997) (22)
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence (2019) (21)
Radiomics Prediction of EGFR Status in Lung Cancer—Our Experience in Using Multiple Feature Extractors and The Cancer Imaging Archive Data (2020) (21)
A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma (2004) (20)
Magnetic resonance cholangiopancreatography (1999) (20)
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. (2015) (20)
Non-Hodgkin lymphoma as a cause of intrahepatic periportal low attenuation on CT. (1997) (20)
Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. (2010) (20)
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) (2017) (19)
Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm (2014) (19)
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma (2008) (19)
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis (2018) (19)
Routine editing of trainee-generated radiology reports: effect on style quality. (2003) (18)
Liver regeneration in humans is characterized by significant changes in cellular phosphorus metabolism: Assessment using proton‐decoupled 31P‐ magnetic resonance spectroscopic imaging (2005) (18)
Prospective, Blinded Comparison of Helical CT and CT Arterial Portography in the Assessment of Hepatic Metastasis from Colorectal Carcinoma (2006) (18)
Assessing outcomes in prostate cancer clinical trials (2008) (18)
[Antioxidant minerals and vitamins. Role in cancer prevention]. (1994) (18)
Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging (2021) (18)
Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. (2017) (18)
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. (2021) (18)
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. (2013) (18)
Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. (2016) (17)
A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. (2005) (17)
Application of the LDM algorithm to identify small lung nodules on low-dose MSCT scans (2004) (17)
A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology (2016) (17)
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. (2014) (17)
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. (2004) (17)
Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma (2008) (17)
Volumetric 3D CT analysis - an early predictor of response to therapy (2007) (17)
Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer (2013) (16)
Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases (2004) (16)
Effects of superparamagnetic iron oxide (AMI-25) on liver and spleen imaging using spin-echo and fast spin-echo magnetic resonance pulse sequences. (1994) (16)
Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients (2011) (16)
Time to tumor growth: a model end point and new metric system for oncology clinical trials. (2013) (16)
Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. (2014) (16)
Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. (2009) (16)
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (2013) (16)
Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors (2004) (16)
Echoplanar MR imaging for characterization of adrenal masses in patients with malignant neoplasms: preliminary evaluation of calculated T2 relaxation values. (1995) (15)
The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival (2013) (15)
Shared Patient Analysis: A Method to Assess the Clinical Benefits of Patient Referrals (2001) (15)
CT-guided automated detection of lung tumors on PET images (2008) (15)
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. (2002) (15)
Prediction of Lymph Node Maximum Standardized Uptake Value in Patients With Cancer Using a 3D Convolutional Neural Network: A Proof-of-Concept Study. (2019) (15)
Imaging of neuroendocrine tumors. (2013) (15)
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. (2016) (14)
Mesenteric adenopathy in patients with prostate cancer: frequency and etiology. (2002) (14)
Implementation Strategy of a CNN Model Affects the Performance of CT Assessment of EGFR Mutation Status in Lung Cancer Patients (2019) (14)
Repeatability of Quantitative Diffusion-Weighted Imaging Metrics in Phantoms, Head-and-Neck and Thyroid Cancers: Preliminary Findings (2019) (14)
Vessel Size Imaging (VSI) by Robust Magnetic Resonance (MR) Relaxometry: MR-VSI of Solid Tumors in Correlation with Immunohistology and Intravital Microscopy (2013) (13)
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. (2012) (13)
Contemporary imaging in sarcoma. (2009) (13)
A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC). (2013) (13)
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021) (13)
Differentiation of Focal-Type Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma Using Radiomics Based on Multiphasic Computed Tomography. (2020) (13)
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. (2003) (13)
Comparison of phased-array and body coils for MR imaging of liver. (1997) (12)
MR enteroclysis: evaluation of small-bowel obstruction in a patient with pseudomyxoma peritonei. (2000) (12)
Patterns of neoplastic spread in colorectal cancer: implications for surveillance CT studies. (1998) (12)
Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. (2020) (12)
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). (2019) (12)
Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). (2013) (12)
Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. (2018) (12)
Automated matching and segmentation of lymphoma on serial CT examinations. (2006) (12)
Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203. (2007) (11)
PreoperativeModified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A 021101 (2019) (11)
Recurrence Patterns of Intraductal Papillary Mucinous Neoplasms of the Pancreas on Enhanced Computed Tomography (2009) (11)
Automatic liver contour segmentation using GVF snake (2004) (11)
Use of Imaging for GI Cancers. (2015) (10)
Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study. (2016) (10)
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study (2018) (10)
Using a single abdominal computed tomography image to differentiate five contrast-enhancement phases: A machine-learning algorithm for radiomics-based precision medicine. (2020) (10)
Soft Tissue Edema Around Musculoskeletal Sarcomas at Magnetic Resonance Imaging (1997) (10)
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy (2004) (10)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
Imaging approaches with advanced prostate cancer: techniques and timing. (2014) (10)
CT bone window photography in patients with cancer. (1995) (10)
Lymph node segmentation by dynamic programming and active contours. (2018) (10)
Quantitative Imaging Metrics Derived from Magnetic Resonance Fingerprinting using ISMRM/NIST MRI System Phantom: An International Multi-Center Repeatability and Reproducibility Study. (2021) (10)
Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT (2020) (9)
Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy (2013) (9)
A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma (2020) (9)
Multicenter Repeatability Study of a Novel Quantitative Diffusion Kurtosis Imaging Phantom (2019) (9)
CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? (1997) (9)
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial (2020) (9)
Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue. (2013) (9)
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer (2019) (9)
MR Imaging of Bone Marrow in Patients with Musculoskeletal Tumors (1999) (8)
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2013) (8)
Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. (2017) (8)
Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer (2021) (8)
Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients (2021) (8)
Assessment of Neurovascular Involvement by Malignant Musculoskeletal Tumors (1997) (8)
PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses (2016) (8)
Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. (2017) (8)
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. (2015) (8)
Evaluation of focal liver lesions: fast-recovery fast spin echo T2-weighted MR imaging. (2006) (8)
The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI (2019) (7)
The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. (2011) (7)
A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). (2019) (7)
Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy (2021) (7)
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. (2020) (7)
Response phenotype as a predictive biomarker to guide treatment with targeted therapies. (2013) (7)
Multi-site, multi-platform comparison of MRI T1 measurement using the system phantom (2021) (7)
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. (2008) (7)
Oncology clinical trials (2013) (7)
Effect of CT image acquisition parameters on diagnostic performance of radiomics in predicting malignancy of pulmonary nodules of different sizes (2021) (7)
Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC). (2012) (6)
Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer (2005) (6)
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. (2021) (6)
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation (2020) (6)
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). (2019) (6)
Distinguishing benign and malignant lesions on contrast-enhanced breast cone-beam CT with deep learning neural architecture search. (2021) (6)
Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. (2019) (6)
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma (2004) (6)
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib (2015) (6)
Predicting death or recurrence of portal hypertension symptoms after TIPS procedures (2022) (5)
Prognostic significance of adrenal gland morphology at CT in patients with three common malignancies. (2012) (5)
Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology? (2021) (5)
Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?, (2011) (5)
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy (2022) (5)
Automated segmentation of mesothelioma volume on CT scan (2005) (5)
81 Development of a computer method for volumetric response assessment in mesothelioma (2006) (5)
A birdcage resonator for intracavitary MR imaging. (1993) (5)
Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. (2004) (5)
Phase II Study of a Non‐Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas (2016) (5)
Advances in magnetic resonance imaging: applications in body imaging. (1998) (5)
Review and interpretation of MR imaging studies with PACS: creating uniform series descriptors for radiologists and referring physicians. (2002) (4)
Artificial Intelligence and Early Detection of Pancreatic Cancer (2021) (4)
MR imaging after surgery for musculoskeletal neoplasm. (2002) (4)
Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions (2021) (4)
Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC (2017) (4)
Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning (2021) (4)
Don't overlook spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development. (2021) (4)
Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. (2006) (4)
Randomized phase II study of hepatic arterial embolization of hepatocellular carcinoma (HCC) with micospheres alone (bead block (BB)) versus doxorubicin loaded microspheres (LC bead (LCB)) (2014) (4)
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (2017) (4)
Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker. (2019) (4)
MR/ultrasound fusion-guided biopsy in prostate cancer: what is the evidentiary standard? (2015) (4)
Advances in cross-sectional imaging of colorectal cancer. (1999) (4)
Early clinical and toxicological results of a combi nation of natural glycolysis inhibitors (METABLOC™) on cancer patients. (2012) (4)
318 Effects of Radiologic Tumor Response of Anti-Glypican-3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular Carcinoma (2012) (3)
Assessing changes in tumor size with CT scans in lung cancer: are volumetric measurements better than unidimensional (1D) and bidimensional (2D) assessments? (2008) (3)
CASE REPORT Endometrial Stromal Sarcoma: Objective Response to Letrozole (2001) (3)
Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions. (2021) (3)
Hepatic arterial infusion (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response (2005) (3)
Imaging and prostate cancer (1996) (3)
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans (2021) (3)
CT radiomic analysis using lymph-node-density profile in correlation to SUV-value for PET/CT based N-Staging (2016) (3)
Advances in imaging. (1994) (3)
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria. (2015) (3)
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170). (2014) (3)
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. (2022) (3)
Role of radiomics to differentiate benign from malignant pheochromocytomas and paragangliomas on contrast enhanced CT scans. (2019) (3)
Feasibility of Using Limited-Population-Based Average R 10 for Pharmacokinetic Modeling of Osteosarcoma Dynamic Contrast-Enhanced MRI Data (2009) (2)
Radiomic signatures for identification of tumors sensitive to nivolumab or docetaxel in squamous non-small cell lung cancer (sqNSCLC) (2019) (2)
The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. (2018) (2)
A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [18F]FDG PET/CT: a pathology-controlled study (2022) (2)
Monitoring Responses to Therapy in Oncology (2014) (2)
Chapter 17 – Magnetic resonance imaging of the liver, biliary tract, and pancreas (2012) (2)
Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline 18F-FDG PET/CT in Metastatic Melanoma (2021) (2)
Novel methodology of response assessment in hepatocellular carcinoma (HCC) -Assessing response by change in tumor enhancement in distinction from conventional means. (2004) (2)
Evaluation of number of target lesions to analyze in time to progression by RECIST (2007) (2)
Development of a Queriable Database for Oncology Outcome Analysis (2008) (2)
Letter to the Editor re: Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer (2013) (2)
A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology (2019) (2)
Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network (2020) (2)
Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer. (2023) (2)
Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib. (2015) (2)
Chapter 2 – Surgical and radiologic anatomy of the liver, biliary tract, and pancreas (2017) (2)
Adenocarcinoma of the distal esophagus and gastroesophageal junction (1989) (2)
Measuring tumor burden: comparison of automatic and manual techniques (2004) (2)
Measuring hepatic metastases to colon cancer. (2006) (1)
Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (2009) (1)
Response to neoadjuvant chemotherapy as measured by PET predicts outcome after liver resection for colorectal metastases. (2006) (1)
Quantitative imaging using CT (2019) (1)
3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria (2015) (1)
Diagnosis and treatment of focal nodular hyperplasia (1996) (1)
The who and what of imaging in sarcoma and correlation with survival. (2015) (1)
Dynamic contrast enhanced MRI (DCE-MRI) to measure antiangiogenic therapy and predict treatment response in primary liver cancer (PLC). (2010) (1)
Radiology pathology conference. A 67-year-old man with a 1-week history of right upper quadrant pain radiating to the back. (1989) (1)
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
A comparative assessment of the incidence of steatohepatitis seen with modern chemotherapy agents (2005) (1)
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2021) (1)
Outcomes of melanoma brain metastases treated with stereotactic radiosurgery with and without concurrent immune checkpoint therapy. (2017) (1)
Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non???squamous NSCLC: P3-097 (2007) (1)
Reply to G. Keramida et al. (2015) (1)
The Role of Novel Imaging Techniques in Clinical Trials (2018) (1)
819 Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp (2021) (1)
Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib. (2017) (1)
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2014) (1)
Utility of an Informational Intranetin a Radiology Department (2003) (1)
QIN. Promise and pitfalls of quantitative imaging in oncology clinical trials (2012) (1)
Fluorodeoxyglucose Positron EmissionTomography as an Outcome Measure for CastrateMetastatic Prostate CancerTreatedwith Antimicrotubule Chemotherapy (2005) (1)
Characterization of Renal Masses with Diffusion-Weighted MR Imaging-- A Preliminary Experience (2007) (1)
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. (2023) (1)
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? (2011) (1)
Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro). (2018) (1)
The Impact of Image Acquisition Parameters and ComBat Harmonization on the Predictive Performance of Radiomics: A Renal Cell Carcinoma Model (2022) (1)
Comparing single-shot RARE and multislice HASTE sequences. (1999) (1)
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM (2009) (1)
P3-097: Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non–squamous NSCLC (2007) (1)
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. (2022) (1)
Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (2015) (1)
Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial NCCTG N1048 (Alliance). (2018) (1)
CONTRAST-ENHANCED ULTRASOUND MONITORING OF PERFUSION CHANGES IN HEPATIC NEUROENDOCRINE METASTASES AFTER SYSTEMIC VERSUS SELECTIVE ARTERIAL (2013) (1)
Impact of normal tissue uptake using 68 Ga DOTATOC-PET/CT in patients with neuroendorcine tumor - a follow-up study (2012) (1)
Reply to E.M. Gilles (2012) (1)
Colorectal Cancer Imaging (2007) (1)
Reproducibility of computed tomography (CT) measurements of lung cancer (2008) (1)
Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer (2005) (1)
Toward radiomics for assessment of response to systemic therapies in lung cancer (2020) (1)
Imaging in oncology: From unknown primary to therapy response assessment (2002) (0)
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
Phase I Evaluation ofJ 591 as a Vascular Targeting Agent in Progressive SolidTumors (2007) (0)
Using virtual clinical trials to determine the accuracy of AI-based quantitative imaging biomarkers in oncology trials using standard-of-care CT (2022) (0)
Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer. (2006) (0)
CirculatingTumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (0)
Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT). (2018) (0)
MO‐C‐AUD‐01: The Emerging Role of Imaging as a Biomarker for Response (2007) (0)
ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus (2007) (0)
Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer 1 (2003) (0)
410 Diagnostic imaging in oncology: New challenges and changing strategies (1996) (0)
Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202. (2021) (0)
Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer (2006) (0)
A Machine-learning Signature Performs as Well as Experts' Consensus to Diagnose Pelvic Lymph Node Involvement in Bladder Cancer on [18F]-FDG PET/CT: A Pathology-controlled Study (2021) (0)
Semi-automated validation of centralized independent review of radiological data in the OPUS trial. (2014) (0)
The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (2011) (0)
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). (2020) (0)
Response assessment parameters in esophageal cancer - conventional and novel techniques. (2004) (0)
Improving outcome of liver resection in patients with colorectal metastases (2008) (0)
Correction to: A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma (2020) (0)
Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer (2007) (0)
Quantitative Osteosarcoma DCE-MRI : How Long is the Acquisition Time Necessary ? (2009) (0)
Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
ponse Evaluation to Aid Biomarker Development (2010) (0)
Abstract No. 354 EE: Standardized Advanced Imaging for Tumor Response Assessment in Clinical Trials for Image Guided Interventions (2008) (0)
of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer (2020) (0)
Utility of an informational intranet in a radiology department. (2003) (0)
Intracavitary birdcage resonator: Applications to the human prostate (1995) (0)
132 A phase I and pharmacokinetic clinical trial of subcutaneous (sc) VEGF trap in advanced solid tumor patients (2004) (0)
P2.11-30 Effects of the Size of Nodules, Reconstruction Slice Thickness and Convolution Kernel on Radiomics Model in Classifying Pulmonary Nodules (2019) (0)
Abstract PO022: Multidimensional longitudinal assessment of patients under treatment for advanced endometrial cancer: a new tool to advance research on human disease (2021) (0)
1019 Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts (2012) (0)
Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC). (2022) (0)
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model (2014) (0)
Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis (2022) (0)
Tumor contrast retention immediately following embolization predicts subsequent radiologic tumor necrosis after bland and drug eluting bead embolotherapy of HCC (2013) (0)
Imaging the liver: Selected topics (2002) (0)
CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study (2018) (0)
Cross-sectional imaging for HPB disorders (MRI and CT) (2010) (0)
Solid Tumor Response Criteria (2021) (0)
Erratum to: Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population (2010) (0)
Abstract 3832: Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group (2012) (0)
The EGF Receptor (EGFR) Continues to Be a Promising Target in NSCLC (2014) (0)
PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC) (2007) (0)
Quantitative contrast peritoneography for intraperitoneal chemotherapy. (2012) (0)
Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. (2017) (0)
review Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence (2010) (0)
The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy. (2020) (0)
SU‐E‐CAMPUS‐J‐02: Exploring Appropriate CT Acquisition Parameters for Measuring Tumor Volumes in Response Assessment Using An Anthropomorphic Thorax Phantom (2013) (0)
Novel biomarkers in NSCLC: Radiomic analysis, kinetic analysis, and circulating tumor DNA. (2022) (0)
Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary (2016) (0)
Qualification of FDG PET/CT as an oncologic biomarker: A methodology demonstration for lymphoma (2012) (0)
Real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes (PROs) in a phase II clinical trial. (2012) (0)
Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
A phase II study for prostate cancer monitoring using 18F-DCFPyL and blood-based biomarkers. (2019) (0)
Metrics for measuring tumor burden: A comparison of unidimensional and volumetric measurements. (2011) (0)
Relationship of variability in tumor measurement and response assessment. (2012) (0)
Medical imaging and its use in clinical trials (2005) (0)
Phase I Clinical Trial of Histone Deacetylase Inhibitor : Suberoylanilide Hydroxamic Acid Administered Intravenously 1 (2003) (0)
Book reviewMR Imaging of the Body, E.J. Rummeny, P. Reimer, W. Heindel (Eds.), Thieme, New York/Stuttgart (2009), p. 690, 1350 illustrations, $USA199.95, ISBN: 978-3-13135-841-7 (2010) (0)
Abstract 5451: Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response (2020) (0)
Quality Assurance of Clinical Trials in the Management of Cancer in the Head and Neck (2011) (0)
Retrospective analysis of standard-of-care imaging in patients with cutaneous T-cell lymphoma (2021) (0)
Assessment of response to treatment (2009) (0)
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. (2020) (0)
Minor response rate to predict patient survival. (2013) (0)
Magnetic Resonance Imaging of the Liver, Pancreas, and Biliary Tract (2007) (0)
P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial (2022) (0)
Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance). (2021) (0)
SU‐E‐T‐40: Exploring the Reproducibility of Tumor Volumes Measured by Radiologist, Computer‐Aided Radiologist and Computer Alone (2011) (0)
Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer. (2004) (0)
Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer (2004) (0)
Convolutional Neural Network Addresses the Confounding Impact of CT Reconstruction Kernels on Radiomics Studies (2021) (0)
586 Response assessment classification: effect of multiple measurement criteria and parameters (2004) (0)
On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer (2021) (0)
TU-A-12A-07: CT-Based Biomarkers to Characterize Lung Lesion: Effects of CT Dose, Slice Thickness and Reconstruction Algorithm Based Upon a Phantom Study. (2014) (0)
Evaluation o f T umor M easurements i n O ncology: U se o f Film-Based a nd E lectronic T echniques (2000) (0)
Prospective evaluation of 18F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases (2021) (0)
Estimating the accuracy and precision of quantitative imaging biomarkers as endpoints for clinical trials using standard-of-care CT (2022) (0)
Comparing true tumor volume to unidimensional and bidimensional measurements in lung cancer-A better discriminator of response? (2006) (0)
Intraperitoneal Chemotherapy For The Treatment Of Malignant Peritoneal Mesothelioma (2015) (0)
Diffusion-weighted MRI and (68)Ga-DOTATOC PET for early monitoring of response to loco-regional (90)Y-/(177)Lu-DOTATOC therapy in patients with neuroendocrine liver metastases (2012) (0)
Prostate Cancer: Systemic therapy (2008) (0)
Book reviewAbdominal–pelvic MRI, 2nd ed, R.C. Semelka (Ed.), Wiley, Hoboken (NJ) (2006), [1427 pages, 1500 illustrations, US$295.00], ISBN: 0471692735 (2006) (0)
Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials. (2013) (0)
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. (2008) (0)
Cystic Neoplasms of the Pancreas: Diagnosis and imaging (2009) (0)
Computers in Radiology (2002) (0)
A Multi-Institutional Biomarker Study of Large B-cell Lymphomas in FDG PET/CT - Experiences within the Oncology Biomarker Qualification Initiative (OBQI) (2016) (0)
Progression-Free Survival The Imaging Viewpoint: How Imaging Affects Determination of (2013) (0)
Oncogene Inactivation Survival and Death Signals Can Predict Tumor Response to Therapy After (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence Howard Schwartz?

Lawrence Howard Schwartz is affiliated with the following schools:

Brown University
Institute of Cancer Research
Yale University
Paris-Saclay University
Cornell University
Columbia University
King's College London